Logo
Logo


ISSN: 0300-9041
ISSNe: 2594-2034

Indizada en: SciELO, Índice Médico Latinoamericano, LILACS, Medline
Editada por la Federación Mexicana de Colegios de Obstetricia, y Ginecologia AC
Fundada por la Asociación Mexicana de Ginecología y Obstetricia en 1945
 

Registro
Iniciar sesión

INFORMACIÓN EXCLUSIVA PARA LOS PROFESIONALES DE LA SALUD

Periodicidad: continua
Abreviatura: Ginecol Obstet Mex
ISSN: 0300-9041
ISSNe: 2594-2034
Indizada en: Scimago, Índice Médico Latinoamericano, Lilacs, Medline, Science Citation Index, Ulrich, Ebsco.

Suplemento

Anticonceptivos inyectables combinados

Combined injectable contraceptives.

Ginecol Obstet Mex. 2020;88(Supl 1):S32-S41.

https://doi.org/10.24245/gom.v88iSupl1.3844

María Soledad Vallejo-Maldonado

Clínica Quilín, Universidad de Chile, Santiago de Chile.


Debe citarse como:

Vallejo-Maldonado MS. Anticonceptivos inyectables combinados. Ginecol Obstet Mex. 2020;88(Supl 1):S32-S41. https://doi.org/10.24245/gom.v88iSupl1.3844

Resumen

Los anticonceptivos inyectables combinados se desarrollaron para evitar los efectos adversos que provocaban los inyectables con solo progestina, además de la supresión del patrón de sangrado menstrual (efecto que no ocurre con los anticonceptivos inyectables combinados). Esta presentación previene la ovulación en 99% de los casos, siempre y cuando se aplique de manera correcta y regular. En los últimos años los anticonceptivos inyectables combinados han ganado mayor aceptación, debido a la comodidad de su administración y provocan menor riesgo metabólico. Los anticonceptivos inyectables combinados constituyen un excelente método para las mujeres que no tienen buen apego al tratamiento con los anticonceptivos orales y se sienten más cómodas con la inyección mensual.

PALABRAS CLAVE: Anticonceptivos inyectables combinados; progestina; acetato de medroxiprogesterona.

Abstract

Combined injectable contraceptives were developed to avoid the adverse effects caused by progestin injections in monotherapy, in addition to the suppression of the pattern of menstrual bleeding (effect that does not occur with combined injectable contraceptives). This presentation prevents ovulation in 99% of cases, as long as it is applied correctly and regularly. In recent years, combined injectable contraceptives have gained greater acceptance, due to the convenience of their administration and lower metabolic risk. Combined injectable contraceptives are an excellent method for women who do not have good adherence to oral contraceptive treatment and feel more comfortable with the monthly injection.

KEYWORDS: Combined injectable contraceptives; Progestin; Medroxyprogesterone acetate.

    1. Ginecología y planificación familiar. Historia de los métodos anticonceptivos. http://www.insexbcn.com/html/anticonceptivos.html.
    2. Coutinho EM, et al. Contraception control by monthly injections of medroxyprogesterone suspension and long- acting oestrogen. J Reprod Fertil 1968;15:209-14.
    3. Department of Economy and Social Affairs. Trends in Contraception Worldwide 2015, UNDESA. http://www.un.org/en/development/desa/population/publications/pdf/family/trendsContraceptiveUse2015Report.pdf.
    4. Henshaw SK. Abortion incidence and services in the United States, 1995-1996. Fam Plann Perspect 1998;30:263-70, 287.
    5. Moreau C, et al. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007;76:267-72.
    6. Hatcher RA, et al. Contraceptive technology 1990-1992, 15th Ed. New York: Irvington Publishers, 1994.
    7. Trussell J, et al. Contraceptive failure, method related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64-93.
    8. Shulman LP. Contraception 2000: Lunelle, an injectable combination contraceptive option. J Womens Health Gend Based Med 2000;9:725-729. https://doi.org/10.1089/15246090050147637
    9. Kaunitz AM. Injectable contraception. New and existing options. Obstet Gynecol Clin North Am 2000;27:741-80.
    10. Goldberg AB, et al. Injectable contraceptives. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart F, Kowal D, editors. Contraceptive Technology. 19th ed. New York: Irvington Publishers, 1998.
    11. Bassol S, et al. Review of ovulation return upon discontinuation of once-a-month injectable contraceptives. Contraception 1994;49:441-53.
    12. Bahamondes L, et al. Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem. Contraception 1997;55:307-10.
    13. World Population Crisis Committee Injectable Contraceptives: safe, effective but neglected. Population policy information kit. Quest Answ 1992;7:1-3.
    14. Haiba NA, et al. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters. Contraception 1989;39:619-32.
    15. Meng YX, et al. Hemostatic changes in women using a monthly injectable contraceptive for one year. Contraception 1990;42:455-66.
    16. United Nations Development Programme United Nations Populations Fund/World Health Organization/World Bank Special Programme of Research, Development and Research training in Human Reproduction. Task Force on Long-acting Systemic Agents for Fertility Regulation. Comparative study of the effects of two once a month injectable contraceptive (Cyclofem and Mesigyna) and one oral contraceptive (Ortho novum 1/359 on coagulation and fibrinolysis. Contraception 2003;68:159-76.
    17. United Nations Development Programme/United Nations Populations Fund/Word Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. Comparative study of the effects of two once a month injectable steroidal contraceptive (Mesigyna and Cyclofem) on lipid and lipoprotein metabolism. Contraception. 1997;56:193-207.
    18. Gordon DJ, et al. High-density lipoprotein cholesterol and cardiovascular disease, four prospective American studies. Circulation 1989;79:8-15.
    19. Jacobs DR, et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131:32-47.
    20. Bass KM, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209-16.
    21. Canto de Cetina TE, et al. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections. Contraception 2004;69:115-9.
    22. Lopez LM, et al. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2014;30. https://doi.org/10.1002/14651858.CD006133.pub5
    23. Farris M, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis. Expert Rev Clin Pharmacol 2017;10:1129-44. https://doi.org/10.1080/17512433.2017.1356718.
    24. Gallo MF, et al. Combination injectable contraceptives for contraception. Cochrane Database Syst Rev 2008;8. https://doi.org/10.1002/14651858.CD004568.pub3.
    25. World Health Organization. Medical eligibility criteria for contraceptive use Fifth edition, 2015. http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf.
    26. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproductions. Task force on long-acting systemic agents for fertility regulation. A multicenter phase III comparative study of two hormonal contraceptive preparations given once a month by intramuscular injection. Contraceptive efficacy and side effects. Contraception 1988;37:1-20.
    27. Kaunitz AM. Injectable contraception. In: Sciarra JJ. Gynecology and Obstetrics. 1st ed. Philadelphia: Lippincott, 1999.
    28. Roy G. Injectable contraception. Semin Reprod Med 2010;28:126-32. https://doi.org/10.1055/s-0030-1248137.
    29. Molina RC, et al. Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents. J Pediatr Adolesc Gynecol 2009;22:25-31. https://doi.org/10.1016/j.jpag.2008.07.010.
    30. Bassol S, et al. Mesigyna Once-a-month combined injectable contraceptive: Experience in Latin America. Contraception 2000;61:309-316. https://doi.org/10.1016/j.jpag.2008.07.010.
    31. A multicenter phase III comparative study of two hormonal contraceptive preparations given once a month by intramuscular injection. II The comparison of bleeding patterns. World Health Organization, special programme of research development and research training in human reproduction. Task force on long -acting systemic agents for fertility regulation. Contraception 1989;40:531-51.
    32. Fotherby K, et al. A preliminary pharmacological trial of the monthly injectable contraceptive cycloprovera. Contraception 1982;25:261-72.
    33. Thurman A, et al. Medroxyprogesterone acetate and estradiol cypionate injectable suspensión (Cyclofem) monthy contraceptive injection: steady state pharmacokinetics. Contraception 2013;87:738-43.
    34. Rahimy MH, et al. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. Contraception 1999;60:209-14.
    35. Coutinho EM, et al. Comparison of two regimens of a monthly injectable contraceptive containing dihydroxyprogesterone acetophenide and estradiol enanthate. Contraception. 2006; 73:249-52. https://doi.org/10.1016/j.contraception.2005.08.016

Comentarios